September 17, 2026
Novo’s third AI partnership in 2026 matters less for today’s revenue than for what comes after generics arrive.
Novo announced a lot on Wednesday. A rebrand to a single name. Forty-four abstracts heading to a European diabetes meeting. And, most consequentially for long-term investors, a collaboration with Anthropic to run drug discovery on Claude Science, the AI research workbench Anthropic launched in June.
A Pound of Gold Pays Your Annual Salary Now
In 1971, the average U.S. wage bought 125 pounds of gold. Today it buys just one. Under the guise of strengthening it, a 55-year policy has eroded the dollar’s purchasing power. Weiss Ratings senior analyst Gavin Magor calls this “Project Pyramid.” Foreign nations have noticed too. Global gold reserves are up 130% since 2015, while dollar reserves are at an all-time low.
The Anthropic deal is the third major AI partnership Novo has announced in 2026, following agreements with OpenAI and Amazon Web Services earlier in the year. The accumulation is not coincidence. It is a signal about where management believes the company’s value will be created, or lost, over the next decade.
To understand why that matters, start with the competitive situation right now. Investors were rattled when Novo’s next-generation weight-loss drug CagriSema delivered disappointing results against Eli Lilly’s tirzepatide, sending the stock sharply lower. Analysts have also cut peak sales forecasts for CagriSema after those results, and Novo has flagged a 2026 sales decline (adjusted for a 340B provision reversal) as competition and pricing pressure intensify. Novo shares last closed at about $42.53 on September 15, 2026, down about 2.1% that day.
That pressure is only the near-term problem. The longer-term one is the patent calendar. Novo itself has said key active-ingredient patent expiries for Ozempic and Wegovy in China fall in 2026, with other major markets extending into the early 2030s. In India, local reporting and industry coverage around the March 2026 expiry has pointed to a wave of branded generics, with around 50 brands expected to enter. Pricing estimates for India have ranged far above $15 per month, with some manufacturers and outlets citing starter-dose pricing closer to about $14 per month in the lowest-cost vial segment.
Urgent: The “Blue-Chip” Crypto Smart Money Is Hoarding
This battle-tested platform has weathered every market cycle and is now processing more volume than ever while still trading at a massive discount. Smart money caught on months ago.
Retail? So far, not informed. That’s why it’s still priced so low. We don’t expect that to last.
Revealed: The blue-chip token set to lead the market surge – yours for only $3!
This is the context in which the Anthropic collaboration deserves to be read. The partnership is designed to address key drug discovery challenges identified by Novo’s scientists and computational teams, with Novo testing Claude Science for specific R&D workflows first. Novo will also use Anthropic’s frontier models to strengthen AI-driven software development, which it describes as a key enabler for scaling AI across the organization.
Claude Science gives users a generalist coordinating agent wired into more than 60 curated skills and connectors pre-configured for genomics, single-cell analysis, proteomics, structural biology, and cheminformatics. The practical bet is that this infrastructure compresses the timeline from molecule to clinical candidate, precisely the stage where Novo needs to rebuild credibility after CagriSema’s stumbles.
CEO Mike Doustdar said the collaboration will “supercharge” the R&D organization, adding that AI can increase productivity and compress the path from research to marketed product while opening new scientific opportunities in understanding human biology and drug mechanics. Anthropic CEO Dario Amodei has argued more broadly that AI could dramatically accelerate scientific progress, including in biology and medicine.
5 Little-Known Stocks Behind Today’s Defense Tech Shift
Behind the headlines, a major transformation is underway.
Modern warfare is being driven by AI, autonomous systems, and next generation technology. A handful of lesser known companies are helping power this shift.
This report uncovers five stocks quietly playing a critical role in the future of defense.
That framing is aspirational. No AI-discovered drug has cleared the FDA yet, and the pharmaceutical industry has yet to fully realize the benefits of its substantial AI investments, with some AI-discovered drug candidates currently in human trials but none approved. The honest read is that this deal does not solve the CagriSema problem or arrest the generic wave hitting emerging markets right now.
What it might do is change the 2030s. Novo’s pipeline candidate amycretin, a dual GLP-1 and amylin agonist, has shown weight-loss and glycemic effects in Phase 2, with Novo advancing it into Phase 3 programs in 2026 across obesity and type 2 diabetes. If Claude Science shortens the cycle time on follow-on molecules and helps Novo identify the next generation of targets before Lilly locks them up, the Anthropic deal earns its place in the investment case.
For investors weighing NVO at a forward earnings multiple that screens well below Lilly’s and below the broader industry, the question is whether the discount prices in too much terminal pessimism. Novo has said that beyond active-ingredient patents it also holds other patents on manufacturing processes, formulations, or uses that can matter for exclusivity past those dates, and a company deliberately wiring frontier-AI partners into its R&D engine is not a company managing decline. It is one trying to rebuild its pipeline faster than the generic wave erodes its current revenue base. That distinction is worth holding onto as Wednesday’s headlines fade.
